Transient CHO expression platform for robust antibody production and its enhanced N-glycan sialylation on therapeutic glycoproteins.

Chinese hamster ovary cells N-linked glycosylation and sialylation antibody therapeutic glycoproteins transient and stable expression

Journal

Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292

Informations de publication

Date de publication:
01 2019
Historique:
received: 09 07 2018
revised: 24 09 2018
accepted: 24 09 2018
pubmed: 10 10 2018
medline: 22 1 2020
entrez: 10 10 2018
Statut: ppublish

Résumé

Large-scale transient expression in mammalian cells is a rapid protein production technology often used to shorten overall timelines for biotherapeutics drug discovery. In this study we demonstrate transient expression in a Chinese hamster ovary (CHO) host (ExpiCHO-S™) cell line capable of achieving high recombinant antibody expression titers, comparable to levels obtained using human embryonic kidney (HEK) 293 cells. For some antibodies, ExpiCHO-S™ cells generated protein materials with better titers and improved protein quality characteristics (i.e., less aggregation) than those from HEK293. Green fluorescent protein imaging data indicated that ExpiCHO-S™ displayed a delayed but prolonged transient protein expression process compared to HEK293. When therapeutic glycoproteins containing non-Fc N-linked glycans were expressed in transient ExpiCHO-S™, the glycan pattern was unexpectedly found to have few sialylated N-glycans, in contrast to glycans produced within a stable CHO expression system. To improve N-glycan sialylation in transient ExpiCHO-S™, we co-transfected galactosyltransferase and sialyltransferase genes along with the target genes, as well as supplemented the culture medium with glycan precursors. The authors have demonstrated that co-transfection of glycosyltransferases combined with medium addition of galactose and uridine led to increased sialylation content of N-glycans during transient ExpiCHO-S™ expression. These results have provided a scientific basis for developing a future transient CHO system with N-glycan compositions that are similar to those profiles obtained from stable CHO protein production systems. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 35: e2724, 2019.

Identifiants

pubmed: 30299005
doi: 10.1002/btpr.2724
doi:

Substances chimiques

Polysaccharides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2724

Informations de copyright

© 2018 American Institute of Chemical Engineers.

Auteurs

Xiaotian Zhong (X)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Weijun Ma (W)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Caryl L Meade (CL)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Amy S Tam (AS)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Eliza Llewellyn (E)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Richard Cornell (R)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

Kaffa Cote (K)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

John J Scarcelli (JJ)

Cell Line Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

Jeffrey K Marshall (JK)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

Boriana Tzvetkova (B)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

Bruno Figueroa (B)

Bioprocessing Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

Dana DiNino (D)

Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc., Andover, Massachusetts, 01810.

Annette Sievers (A)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Christopher Lee (C)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Jane Guo (J)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Evan Mahan (E)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Christopher Francis (C)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Khetemenee Lam (K)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Aaron M D'Antona (AM)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Richard Zollner (R)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Hongli L Zhu (HL)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Ron Kriz (R)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Will Somers (W)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Laura Lin (L)

BioMedicine Design, Medicinal Sciences, Pfizer Worldwide R&D, Cambridge, Massachusetts, 02139.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH